Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
Gary W Pace bought 361,615 shares of CRDF on 11 December at $2.60 per share, worth a total of $940K. They now own 1,059,376 CRDF shares, or a 52% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
